30 closest matches · ranked by relevance
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Caregiver · Malignant Head and Neck Neoplasm · Paranasal Sinus Squamous Cell Carcinoma
Primary: Number of Participants Noting Quite a Bit/Very Much Helpful to Survey Questions — 4; 6; 7; 6 Participants
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
Head and Neck Cancer
Primary: Rate of Movement of Normal Tissue
Head and Neck Cancer
Primary: Compliance With Treatment . — 74 percentage of participants
Head and Neck Cancer
Primary: Response Probability (Confirmed Complete and Partial Responses) — 0; 2; 38 participants
Locally Advanced Basal Cell Carcinoma · Skin Cancer · Cutaneous Malignancy
Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Head and Neck Neoplasms · Malignant Neoplasm of Vertebral Column
Primary: Number of Participants Undergoing Image-guided Cryoablation of a Head, Neck, or Spine Tumor With Adverse Events — 3; 0 participants
Head and Neck Cancer
Primary: Incidence of Treatment Related Adverse Events — 4; 2; 4; 1 Participants
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Non-HPV Locally Advanced Head and Neck Cancer
Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 34.6; 43.1 percentage of participants — p=0.3436
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Head and Neck Cancer
Primary: Change in Body Image Scale Score From Baseline to 1-month Post-intervention — -3.5; -0.7 score on a scale — p=0.25
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Head or Neck Cancer
Primary: Overall Response Rate — 2; 5 Participants
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
Head and Neck Cancer
Primary: Overall Survival (Percentage of Participants Alive) — 64.3; 70.3 percentage of patients — p=0.180
Neoplasms, Head and Neck
Primary: Disease Free Survival (DFS) — NA; 53.6 Months — p=0.2251
Head and Neck Cancer
Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013 — 76; 68 participants
Brain and Nervous System · Intracranial Neoplasm · Head and Neck Cancer
Primary: Accuracy Measured by Quantifying the Difference in Translational Shifts From the Daily Setup to Planning CT Scan Digitally Reconstructed Radiograph — 0.08; 0.16; -0.02…
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051